FSD Pharma receives ethics committee approval for a Phase-1 trial of Lucid-MS in Australia.
FSD Pharma, a biopharmaceutical company, receives ethics committee approval for a Phase-1 multiple ascending doses clinical trial of Lucid-21-302 (Lucid-MS) in Australia. Lucid-MS is a novel compound targeting multiple sclerosis and other neurodegenerative diseases. The trial assesses safety and pharmacokinetics in healthy participants, marking a significant milestone in Lucid-MS's clinical development.
June 27, 2024
6 Articles